CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”) ...

Please provide your email address to receive an email when new articles are posted on . Six months after its merger with Novartis was finalized, Alcon is poised to expand its global eye care market in ...

Please provide your email address to receive an email when new articles are posted on . Rumors swirled around the exhibit floor and coursed through gatherings of dry eye disease docs who attended the ...

Narrow-moat Alcon discussed current projects and initiatives, pipeline progression, and long-term financial goals in its 2025 Capital Markets Day. After digesting the performance of each business unit ...

“For more than 25 years, Alcon has been a leader in vitreoretinal surgery, and we are excited to expand our offerings into the clinic, to help millions of people living with dry AMD gain vision,” said ...

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: vision ...

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO ...

Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the ...